Trial
NCT04949191
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Advanced Malignancies
Intervention
Pemigatinib
Why stopped
A business decision due to availability of commercial drug and other options for accessing study drug treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19